I. Introduction
Methylation of the genomic DNA is the most important modification of the eukaryotes which governs the expression of the genome. MECP2 (Methyl-CPG Binding Protein 2) is a DNA binding protein which is present excessively in Nervous system. MECP2 along with other Binding proteins (MBD1, MBD2 etc.) comprise a group of nuclear proteins capable of binding specifically to Methylated CPGs and regulating the cell expression (Na et al., 2013) , as well as engaged in regulation of gene at the post transcriptional level by repressing the Nuclear microRNA . It is reported thatMECP2 has a dual function, it mediates both in repression as well as activation of many genes .
Wide range of mutations and duplications in MECP2 gene have been asserted in Complex Neurological disorders (Smyk et al., 2008) typically Rett syndrome, mental retardation and Autism. Interestingly both polymorphisms and mutations in this gene have been claimed to be involved.Towards this aim the screening of this gene in neurological symptoms is of utter importance which can provide a permanent solution to the congenital and life threatening neurodegenerative diseases.
II. Structure of Methyl-CpG Binding Protein 2(MECP2) Gene
The Methyl-CpG Binding Protein 2 (MECP2) gene is located at X chromosome; q28 and encodes a protein transcriptional regulator methyl-CpG-binding protein 2 that binds to the residues of Methylated cytosine (CpG dinucleotides) and regulate the transcriptional silencing of other genes along with Histone deacetylase and other transcriptional repressors (Hoffbuhr et al., 2002) .
MECP2also regulates the gene expression at post transcriptional level as well as an important factor of neural development. It suppresses the nuclear microRNA processing by specifically binding toDGCR8(DiGeorge syndrome critical region 8), a critical component of the nuclear microRNA machinery thereby regulating the expression of gene. The interaction in turn also target the proteins: CREB, LIMK1, and Pumilio2, necessaryfor the maturation of nervous system and also inhibits the growth of dendritic and spine . Post translational modifications like phosphorylation, SUMOylation, and acetylation have a considerable effect on MECP2 proteinwhich cater more dimensions to its regulatorytasks .
The Transcript/GENE length of MECP2 gene is 10,505 bps, length of Translation/PROTEIN is 486 amino acids and contains 4 Exons (ENSEMBL ID: ENST00000303391.10) as shown in figure 3.1. The isoforms of MECP2 include; MeCP2_e2 in which all four EXONs are present and MeCP2_e1 in which EXON 2 is spliced. The level of expression of these two isoforms differ among tissues, with MeCP2_e1 has the highest expression in brain, whereas MeCP2_e2 is presentsignificantly in liver, placenta and skeletal muscle (Itoh et al.,2012) as shown in figure 3.2. 
III. Functional Domains of MECP2
There are three functional domains of MECP2; Methyl CpG binding domain (MBD), Transcription repressor domain (TRD),C terminal domain (CTD) as shown in figure 3.2.
The Methyl-CPG Binding Domain (MBD)
The methyl-CpG binding domain binds particularly to Methylated-CpGs. It is 85 amino acid long; and is present with exon 3 and 4; and is crucial for chromatin remodeling. Studies have shown that the MBD tailor a wedge-shaped molecular structure as shown in figure 4.1.It contains a hydrophobic pocket having the side chains Tyr123 and Ile125 present on the beta-sheet face is thesite of contact with the Methyl groups of the cytosine residues (Wakefieldet al., 1999) .The N-terminus of the MBD consist of amino acid identical the HMG (high mobility group proteins) that regulate DNA activities such as transcription, translation etc. Recently the interaction between the N-terminal region and theRepressive Chromatin Regulator Heterochromatin protein 1 (HP1) has been shown which is the key factor in formation of transcriptionally inactive heterochromatin (Singh et al., 2008) . 
TheTranscriptional Repressor Domain (TRD)
A transcriptional repression domain 104 amino acid long; present within exon 4; with co-repressor complexes, repress the transcription by the de-acetylation of the histones, with subsequent amendment of DNA into hetero-chromatin (Jones et al., 1998; Nan et al., 1998) . MECP2 interacts with the Sin3A/HDACI or Ski/NcoR/HDACII(repression complexes) to perform this task (Kokura et al., 2001 ). Moreover, MECP2has independent silencing capabilities. This domain also contains the Nuclear Localization Signals (NLS).
The C Terminal Domain (CTD)
This Domain (residues 384-387) particularly binds to WW domains of (group II) Splicing factors including; Formin binding protein II and Huntington yeast protein C. When the binding region of the WW domain was cut short by 48 amino acids present at C terminus, involved in Rett syndrome, caused a decreased or failure of WW domain binding activity. Furthermore, the reduction of the WW domain binding activity is also linked with mild to moderate intellectual disability in males (Buschdorf and Stratling, 2004) . The CTD also contains the chromatin binding regionswhich are needed for the remodeling of the chromatin (Nikitina et al., 2007) . There are common orthologues of MECP2 in monkey, rat, xenopus, mouse, and zebrafish, suggesting the key roles of MECP2 throughout vertebrate evolution (Weaving et al., 2005) .
IV. Spectrum of MECP2 Mutation
The spectrum of MECP2 mutation is broad including; Nonsense mutations, Missense mutations, Missense mutations appear within the Methyl binding domain; (R106W, R133C, F155S and T158M), and one nonsense mutation; (L138X), abolished the precise binding of MECP2 to the methylated DNA which is associated with several neurological phenotypes.Nonsense mutations; (L138X, R186X, E235X, R255X, R270X, V288X and R294X) and two missense mutations; one inside the Transcriptional repressor domain; (R306C) and other one in the C terminal domain; (E397K) were found. The nonsense mutations resulted in non-functional protein product which were unable to suppress the transcription, as opposed to missense mutations which kept the ability to repress the transcription (Timur and Alan, 2000) .
The MECP2 gene has frequent mutations and duplications in wide range of neurological disorder (Villard et al., 2007; Smyk et al., 2008) . It was illustrated that there is a reduced expression MECP2 in 79% of autism samples of cortex (Nagarajanet al., 2006).In Rett syndrome(RTT) patients there is a normal early development superseded by regression and motor anomalies which is attributed to mutations in MECP2 (Mitchel, 2011 ). Females with MECP2 mutations show infantile autism, mild intellectual disability and reserved speech (Percy, 2002; Beyer et al., 2002) . Males display phenotypes including fatal encephalopathy in newborns, severe mental retardation, seizures, tremor, lack of muscle coordination and psychiatric symptoms (Percy, 2002) . Females render milder phenotypesdue to the X-chromosome inactivation generally skewed X-chromosome inactivation occurs (Amir et al., 2000) . It has also been found that the connection between theMECP2 and the
ATRXproteins (chromatin proteins) is disturbed by the mutations which results inintellectual disabilities (Nan et al., 2006).

V. MECP2 as Novel Oncogene
A genome wide sequence has also identified MECP2 as a novel oncogene. Many cell lines of cancer have been elaborated which display overexpression of theMECP2 and rely onMECP2 for their proliferation. The alterations in the MECP2 and the members of RAS family are mutually exclusive in various types of cancer. The isoforms of MECP2 activate signal transduction networks. The recovery of KRAS-cell lines depends upon the MECP2 after the suppression of KRAS in the same way the growth of MECP2-cell lines rely upon KRAS. The binding of the MECP2 to the 5-hydroxymethylcytosine (5hmC) is needed for effective transformation a key to epigenetics. These findings propose that MECP2can be considered as a novel oncogene (Neupaneet al.,  2015) .
VI. Dual Role of MECP2
It is a chromatin-associated protein (Kumar et al., 2008) 
VII. MECP2Expression in Central Nervous System (CNS)
The neurons contain the maximum levels of MECP2, which is originally present at low amounts andraises over the course of neuron development, and reaches its highest level in matured neuron (Balmeret al., 2003) . Studies reveal that the individuals suffering from RTT (Rett syndrome) have lesser population of neurons and their dendrites are less complex as opposed to the control samples further supporting the function of MECP2 in neuronprogression. Cells of Glia also contains observable levels of MECP2protein. It has also beenindicated that the astrocytes possesstheMECP2 expression critical for the RTT phenotypes (Ballaset al., 2009; Maezawaet al., 2009; Gonzales and LaSalle, 2010) . Italso modulate thegenes like Bdnf (brain-derived neurotropic factor) and JUNB. The EGR2 gene (early growth response 2 gene) isneeded for neuronal function as well as early development of hindbrain, has its binding sites in the promoter regions of neuronal genes including MECP2 gene (Swanberget al., 2009 ).
An experiment was conducted in which the expression level ofMECP2protein was kept normal in the nervous system, but is deficient in rest of the body. Wild type and MECP2 deficient mice were then compared and it was shown that the majority of neurological symptoms were absent. However bone abnormalities, fatigue, and hypo-activity was observed, which confirms brain as the primary organ for MECP2 associated phenotypes, but it also suggests that less extreme form of disorder may arise independent of the nervous system (Ross et al., 2016) .
Furthermore there is an increased expression of MECP2 especially in the hippocampus, cortex, and cerebellum which turns out to be associated in neuronal maturation. It has been proved that the MECP2 is found in the post-synaptic compartments of neurons and its nucleus, which implies that theMECP2 has a role in synaptic activity and performs transcription regulation through it (Aber et al., 2004; Weaving et al., 2005) .
The neuronal transcription and retro-transposition of Long interspersed nuclear elements-1L, get elevated in the absence of MECP2 gene. Utilizing human induced pluripotent stem cells, neuronal progenitor cells were acquired, it was explained that the patients with neurologic symptoms, carrying theMECP2 mutations,are vulnerable for L1 retro-transposition. These findings pose anadditional challenge to the molecular events which give rise to the disorders of the CNS (Muotriet al., 2010) .
VIII. MECP2 Duplication Syndrome
Duplications of the Xq28 region (locus of MECP2) are the most frequent chromosomal abnormalities associated with intellectual disability, especially in males. These duplications include interstitial duplications mediated by segmental duplication and terminal duplications. The most commonly duplicated region includes MECP2 gene, with atleast duplicated size of 0.2 Mb. Duplications also occurs in telomeric nearby regions, which include GDP dissociation inhibitor 1 gene (GDI1); and Ras-associated gene (RAB39B); are individually linked with intellectual disabilities. Magnetic Resonance Imaging of brain reveals abnormalities in the white matter, which is consistently found in patients with MECP2 duplications (Yamamoto et al., 2014) . Phenotypes of this duplication includes; decreased muscle tone, delay in psychomotor skills, intellectual disability, apraxia, contraction of muscle, seizures and periodic respiratory infections. Females have also been observed to show milder phenotypes. Most of the affected males die before reaching twenty five. Additionally autistic symptoms and gastrointestinal malfunctioning have also been noted in boys (Pagonet al., 2008) .
IX. Conclusion
Significant amount of findings have been presented concerning the role ofMECP2 gene. The etiology of neurological disorders lies in the complex genetic networks and their interactions. Thus considerable researches have been carried out to analyze the crucial and precise role of MECP2. Interestingly bothrarevariations and common polymorphisms within this geneare found to belinked with the critical phenotypes of CNS, which necessitates the thorough investigation of MECP2, in order to implement practical diagnostic approaches. Various gene therapy approaches have been used based on the available genetic information for treating the neurological disorders. More recent approach involves whole organ being synthesized using reprogrammed stem cells and also repair of damaged tissue using stem cells regenerative therapies which offers a great potential towards the therapy of these complex NDDs.
